Development of a novel therapeutic suppressor of brain proinflammatory cytokine up-regulation that attenuates synaptic dysfunction and behavioral deficits

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 2, 2007, Pages 414-418

  Hu, Wenhui ^a   Ralay Ranaivo, Hantamalala ^a   Roy, Saktimayee M ^a   Behanna, Heather A ^a   Wing, Laura K ^a   Munoz, Lenka ^a   Guo, Ling ^a   Van Eldik, Linda J ^a   Watterson, D Martin ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; Neurodegeneration; Process chemistry; Proinflammatory cytokine; Pyridazine

Indexed keywords

CYTOKINE RECEPTOR ANTAGONIST;

AQUEOUS SOLUTION; ARTICLE; CYTOKINE RELEASE; ENCEPHALITIS; MOLECULAR DYNAMICS; SOLUBILITY; SYNAPTIC MEMBRANE; UPREGULATION;

ALZHEIMER DISEASE; ANIMALS; ASTROCYTES; BEHAVIOR, ANIMAL; BIOLOGICAL AVAILABILITY; BRAIN CHEMISTRY; CHEMISTRY, PHYSICAL; CYTOKINES; DRUG DESIGN; GLIAL FIBRILLARY ACIDIC PROTEIN; HIPPOCAMPUS; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MICROGLIA; NOOTROPIC AGENTS; RATS; SYNAPSES; UP-REGULATION;

EID: 33846151369     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.10.028     Document Type: Article

References (23)

1. Craft J.M., Watterson D.M., and Van Eldik L.J. Expert Opin. Ther. Targets 9 (2005) 887
2. Mrak R.E., and Griffin W.S.T. Neurobiol. Aging 26 (2005) 349
3. Wyss-Coray T. Nat. Med. 12 (2006) 1005
4. Watkins L.R., and Maier S.F. Nat. Rev. Drug Disc. 2 (2003) 973
5. Maini R.N., and Taylor P.C. Annu. Rev. Med. 51 (2000) 207
6. Scott D.L., and Kingsley M.B. N. Engl. J. Med. 335 (2006) 704
7. Tobinick E., Gross H., Weinberger A., and Cohen H. Med Gen. Med. 8 (2006) 25
8. Mpofu S., Fatima F., and Moots R.J. Rheumatology 44 (2005) 271
9. Guo Z., Cupples L.A., Kurz A., Auerbach S.H., Volicer L., Chui H., Green R.C., Sadovnick A.D., Duara R., DeCarli C., Johnson K., Go R.C., Growdon J.H., Haines J.L., Kukull W.A., and Farrer L.A. Neurology 54 (2000) 1316
10. D'Ambrosio R., and Perucca E. Curr. Opin. Neurol. 17 (2004) 731
11. Sams-Dodd F. Drug Discovery Today 11 (2006) 465
12. Wing L.K., Behanna H.A., Van Eldik L.J., Watterson D.M., and Ralay Ranaivo H. Curr. Alzheimer. Res. 3 (2006) 205
13. Ralay Ranaivo H., Craft J.M., Hu W., Guo L., Wing L.K., Van Eldik L.J., and Watterson D.M. J. Neurosci. 26 (2006) 662
14. Velentza A.V., Wainwright M.S., Zasadzki M., Mirzoeva S., Schumacher A.M., Haiech J., Focia P., Egli M., and Watterson D.M. Bioorg. Med. Chem. Lett. 13 (2003) 3465
15. Hu W., Ralay Ranaivo H., Craft J.M., Van Eldik L.J., and Watterson D.M. Curr. Alz. Res. 2 (2005) 197
16. Lipinski C.A., Lombardo F., Dominy B.W., and Feeney P.J. Adv. Drug Delivery Rev. 23 (1997) 3
17. van de Waterbeemd H., Smith D.A., Beaumont K., and Walker D.K. J. Med. Chem. 44 (2001) 1313
18. Wenlock M.C., Austin R.P., Barton P., Davis A.M., and Leeson P.D. J. Med. Chem. 46 (2003) 1250
19. Vieth M., Siegel M.G., Higgs R.E., Watson I.A., Robertson D.H., Savin K.A., Durst G.L., and Hipskind P.A. J. Med. Chem. 47 (2004) 224
20. Veber D.F., Johnson S.R., Cheng H.-Y., Smith B.R., Ward K.W., and Kopple K.D. J. Med. Chem. 45 (2002) 2615
21. Details of synthetic procedures, analytical chemistry methods, physical property determinations, NMR spectra, and biological procedures, including screening data for oral bioavailability and brain uptake, can be found in Supporting Information. Information about the clinical development of compound 17 under the name of Minozac can be accessed on the website of NeuroMedix (NMX) Inc., http://www.neuromedix.com.
22. Wermuth C.G., Schlewer G., Bourguignon J.-J., Maghioros G., Bouchet M.-J., Moire C., Kan J.-P., Worms P., and Biziere K. J. Med. Chem. 32 (1989) 528
23. Wermuth C.G., and Stahl P.H. In: Stahl P.H., and Wermuth C.G. (Eds). Handbook of Pharmaceutical Salts (2002), Wiley-VCH 249